Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 41

Sort by

Sort Order Select

Journal Articles

Disrupting IL10 Signaling Overcomes Compound Copy Number Variation-Driven Clinical Resistance to CDK4/6 and BTK Inhibition in Mantle Cell Lymphoma

Maurizio Di Liberto, Yang Hu, Xiangao Huang, Giorgio Inghirami, Kevin Wang, Christina Y. Lee, Kami J. Maddocks, Kristie A. Blum, Jia Ruan, John P. Leonard, Nancy L. Bartlett, Peter Martin, Olivier Elemento, Selina Chen-Kiang

Blood (2024) 144 (Supplement 1): 831.

https://doi.org/10.1182/blood-2024-209415

Published: 2024

Journal Articles

CDK4/6 Inhibition Reverses MEIS2 Inhibition of CRL4 CRBN By Both Disrupting MEIS2-CRBN Association and Opposing Regulation of MEIS2 and CRBN Synthesis That Enhances IMiD Therapy in Multiple Myeloma

Xiangao Huang, David S Jayabalan, Maurizio Di Liberto, Zhengming Chen, Scott Ely, Roger Pearse, Joseph Lane, Gang Lin, Ruben Niesvizky, Selina Chen-Kiang

Blood (2024) 144 (Supplement 1): 1886.

https://doi.org/10.1182/blood-2024-206115

Published: 2024

Journal Articles

Harnessing Btki Therapy By CDK4/6i Control of T Effector Memory Cells and T Cell Surveillance in Mantle Cell Lymphoma

Maurizio Di Liberto, Yang Hu, Xiangao Huang, Giorgio Inghirami, Kevin Wang, Christina Lee, Kami J. Maddocks, Kristie A. Blum, Jia Ruan, John P. Leonard, Nancy L. Bartlett, Peter Martin, Olivier Elemento, Selina Chen-Kiang

Blood (2023) 142 (Supplement 1): 50.

https://doi.org/10.1182/blood-2023-190308

Published: 2023

Journal Articles

Combined Inhibition of CDK2 and BCL2 Overrides Resistance to Targeting BTK and CDK4/6 in Mantle Cell Lymphoma Therapy

Haya Y. Al-Ansari, Saira Bashir, Adrienne Cui, Xiangao Huang, Yang Hu, Peter Martin, Olivier Elemento, Maurizio Di Liberto, Selina Chen-Kiang

Blood (2022) 140 (Supplement 1): 495–496.

https://doi.org/10.1182/blood-2022-167307

Published: 2022

Journal Articles

Dynamic Immune Surveillance in Durable Clinical Response to Combined BTK and BCL2 Inhibition in MCL at Longitudinal Single-Cell Resolution

Kevin Wang, Maurizio Di Liberto, Yang Hu, Xiangao Huang, Rachel M Koldej, David Ritchie, Peter Martin, Giorgio Inghirami, Olivier Elemento, Constantine S. Tam, Selina Chen-Kiang

Blood (2021) 138 (Supplement 1): 1323.

https://doi.org/10.1182/blood-2021-152908

Published: 2021

Journal Articles

FOXO1 Dependent Transcription Network Is a Targetable Vulnerability of Mantle Cell Lymphoma

Ja-Young Jang, Inah Hwang, Heng Pan, Michael Kluk, Jun Yao, Xiangao Huang, Maurizio Di Liberto, Zhengming Chen, Karla V Ballman, Lewis C Cantley, Giorgio Inghirami, Olivier Elemento, Robert Baiocchi, Selina Chen-Kiang, Sandro Belvedere, Hongwu Zheng, Jihye Paik

Blood (2021) 138 (Supplement 1): 30.

https://doi.org/10.1182/blood-2021-153378

Published: 2021

Journal Articles

Disrupting GRINL1A Association with Cereblon Accelerates IKZF1/3 Degradation and IMiD Killing of Mantle Cell Lymphoma Cells By CDK4/6 Inhibition

Nicole Zhao, Maurizio Di Liberto, PhD, Olivier Elemento, PhD, Selina Chen-Kiang, PhD, Xiangao Huang, PhD

Blood (2019) 134 (Supplement_1): 299.

https://doi.org/10.1182/blood-2019-128927

Published: 2019

Journal Articles

T-Cell Clonal Expansion and Activation Associated with Durable Clinical Response to Dual BTK and CDK4/6 Inhibitor Therapy in Mantle Cell Lymphoma

Christina Y. Lee, MD, Maurizio Di Liberto, PhD, Yang Hu, PhD, Xiangao Huang, PhD, Nancy L Bartlett, MD, Kami J. Maddocks, MD, John P. Leonard, MD, Nils-Petter Rudqvist, PhD, Lorenzo Galluzzi, PhD, Peter Martin, FRCPC, MD MS, Olivier Elemento, PhD, Selina Chen-Kiang, PhD

Blood (2019) 134 (Supplement_1): 3973.

https://doi.org/10.1182/blood-2019-122322

Published: 2019

Journal Articles

Composite Copy Number Variation in CDK4 , CDKN2A and RB1 Predisposes Mantle Cell Lymphoma to Expansion of PD1+ Tumor Cells and Resistance to CDK4/6 Inhibitor Therapy as Revealed by Integrative Longitudinal scRNA-seq

Maurizio Di Liberto, PhD, Yang Hu, PhD, Xiangao Huang, PhD, Christina Y. Lee, MD, Kevin Wang, B.S., Nancy L. Bartlett, MD, LeAnn Ridling, Kristie A. Blum, MD, Kami J. Maddocks, MD, Steven I Park, MD, Jia Ruan, MD PhD, Kenneth Eng, B.S., Lorenzo Galluzzi, PhD, John P. Leonard, MD, Peter Martin, FRCPC, MD MS, Olivier Elemento, PhD, Selina Chen-Kiang, PhD

Blood (2019) 134 (Supplement_1): 1492.

https://doi.org/10.1182/blood-2019-130944

Published: 2019

Journal Articles

A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma

Peter Martin, Nancy L. Bartlett, Kristie A. Blum, Steven Park, Kami Maddocks, Jia Ruan, LeAnn Ridling, Christopher Dittus, Zhengming Chen, Xiangao Huang, Giorgio Inghirami, Maurizio DiLiberto, Selina Chen-Kiang, John P. Leonard

Blood (2019) 133 (11): 1201–1204.

https://doi.org/10.1182/blood-2018-11-886457

Published: 2019

Journal Articles

Cooperative Repression of IRF4 and Induction of IRF7 By CDK4/6 Inhibition Sensitizes Mantle Cell Lymphoma Cells to IMiD-Mediated Apoptosis Independent of p16 Deletion or c-Myc Overexpression

Basel A Humos, Maurizio Di Liberto, PhD, Xiangao Huang, PhD, Olivier Elemento, PhD, Selina Chen-Kiang, PhD

Blood (2018) 132 (Supplement 1): 2864.

https://doi.org/10.1182/blood-2018-99-117487

Published: 2018

Journal Articles

A Phase I Trial of Ibrutinib Plus Palbociclib in Patients with Previously Treated Mantle Cell Lymphoma

Peter Martin, MD, Kristie Blum, MD, Nancy L. Bartlett, MD, Steven I. Park, MD, Kami J. Maddocks, MD, Jia Ruan, MD PhD, Maurizio Di Liberto, PhD, Xiangao Huang, PhD, Giorgio Inghirami, MD, Pamela Harris, MD, Selina Chen-Kiang, PhD, John P. Leonard, MD

Blood (2016) 128 (22): 150.

https://doi.org/10.1182/blood.V128.22.150.150

Published: 2016

Journal Articles

PIK3IP1 Inhibition of PI3K in G1 Arrest Induced By CDK4 Inhibition Reprograms MCL for Ibrutinib Therapy

Maurizio Di Liberto, PhD, Xiangao Huang, PhD, Olivier Elemento, PhD, Ken Eng, Kristie A. Blum, MD, Nancy L. Bartlett, MD, Steven I. Park, MD, Jia Ruan, MD PhD, Kami J. Maddocks, MD, Giorgio Inghirami, MD, Lewis Cantley, MD, John P. Leonard, MD, Peter Martin, MD, Selina Chen-Kiang, PhD

Blood (2016) 128 (22): 610.

https://doi.org/10.1182/blood.V128.22.610.610

Published: 2016

Journal Articles

Cooperative Supression of MEIS2 Mediates Dexamethasone Enhancement of Lenalidomide Killing in Myeloma Cells

Sonia Allouch, David S Jayabalan, BSMS., MSc, Adriana C Rossi, MD, MSc, Ruben Niesvizky, MD, Xiangao Huang, PhD, Selina Chen-Kiang, PhD

Blood (2016) 128 (22): 3292.

https://doi.org/10.1182/blood.V128.22.3292.3292

Published: 2016

Journal Articles

Inhibition of CDK4/CDK6 Sensitizes Myeloma to IMiD By Reducing the MEIS2 to Cereblon Ratio That Accelerates IKZF1 and IKZF3 Degradation

Xiangao Huang, PhD, David Jayabalan, BSMS, MSc, Maurizio Di Liberto, PhD, Zhengming Chen, PhD, Anna C Schinzel, PhD, Scott Ely, MD MPH, Adriana C Rossi, MD MHS, Roger N Pearse, MD PhD, Ekta Aneja, MBBS, Morton Coleman, MD, Joseph M Lane, MD, William C. Hahn, MD PhD, Tomer M Mark, MD MSc, Ruben Niesvizky, MD, Selina Chen-Kiang, PhD

Blood (2015) 126 (23): 500.

https://doi.org/10.1182/blood.V126.23.500.500

Published: 2015

Journal Articles

High-Dose Carfilzomib and Dexamethasone As First-Line Treatment in Symptomatic Multiple Myeloma

Tomer M Mark, MD MSc, Sujitha Yadlapati, MBBS, Lyubov Neglyad, Jennifer Bourke, RN, David Jayabalan, BSMS, MSc, Adriana C Rossi, MD, Roger N Pearse, MD PhD, Arthur Perry, PA, Karen Pekle, NP, Kathleen Pogonowski, RN, Linda Tegnestam, RN, Xiangao Huang, PhD, Maurizio Di Liberto, PhD, Scott Ely, MD MPH, Morton Coleman, MD, Selina Chen-Kiang, PhD, Ruben Niesvizky, MD

Blood (2015) 126 (23): 4258.

https://doi.org/10.1182/blood.V126.23.4258.4258

Published: 2015

Journal Articles

Clapd (Clarithromycin, Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma Overcomes Negative Prognostic Impact of Adverse Cytogenetics and Prior Resistance to Lenalidomide and Bortezomib

Tomer M Mark, MD MSc, Angelique Boyer, Sujitha Yadlapati, MBBS, Adriana C Rossi, MD, Roger N Pearse, MD PhD, Karen Pekle, NP, Arthur Perry, PA, Kathleen Pogonowski, RN, Ekta Aneja, MD, Linda Tegnestam, RN, David Jayabalan, BSMS, MSc, Scott Ely, MD MPH, Morton Coleman, MD, Xiangao Huang, PhD, Maurizio Di Liberto, PhD, Selina Chen-Kiang, PhD, Ruben Niesvizky, MD

Blood (2015) 126 (23): 4232.

https://doi.org/10.1182/blood.V126.23.4232.4232

Published: 2015

Journal Articles

Sensitizing shRNA Screen for Molecular Targets in CDK4/CDK6-Based Combination Therapy in Multiple Myeloma

Xiangao Huang, PhD, Maurizio Di Liberto, PhD, David Chiron, PhD, Ruben Niesvizky, MD, Anna C. Schinzel, PhD, William C. Hahn, MD PhD, Selina Chen-Kiang, PhD

Blood (2014) 124 (21): 3440.

https://doi.org/10.1182/blood.V124.21.3440.3440

Published: 2014

Journal Articles

The Combination Of Palbociclib Plus Bortezomib Is Safe and Active In Patients With Previously Treated Mantle Cell Lymphoma: Final Results Of a Phase I Trial

Peter Martin, MD, Maurizio DiLiberto, PhD, Christopher E Mason, PhD, Scott A Ely, M.D., Jia Ruan, MD, PhD, Richard R. Furman, MD, David Chiron, PhD, Xiangao Huang, PhD, David C Madoff, M.D., Jonathan Navi, Jessica Lewis, PA-C, Alison Bender, PA-C, Amelyn Rodriguez, RN, June Greenberg, RN, Morton Coleman, MD, Selina Chen-Kiang, PhD, John P. Leonard, M.D.

Blood (2013) 122 (21): 4393.

https://doi.org/10.1182/blood.V122.21.4393.4393

Published: 2013

Journal Articles

Integrative Whole Transcriptome and Exome Sequencing Reveals Reprogramming Of Mantle Cell Lymphoma In Prolonged Early G1 Arrest For Clinical Response To Selective Inhibition Of CDK4 In Combination Therapy

David Chiron, PhD, Peter Martin, MD, Maurizio Di Liberto, Ph.D., Xiangao Huang, PhD, Priyanka Vijay, B.A, Pedro Blecua, PhD, Scott A Ely, MD, MPH, Olivier Elemento, PhD, Christopher E Mason, PhD, John P. Leonard, MD, Selina Chen-Kiang, PhD

Blood (2013) 122 (21): 80.

https://doi.org/10.1182/blood.V122.21.80.80

Published: 2013

NARROW

Disrupting IL10 Signaling Overcomes Compound Copy Number Variation-Driven Clinical Resistance to CDK4/6 and BTK Inhibition in Mantle Cell Lymphoma

CDK4/6 Inhibition Reverses MEIS2 Inhibition of CRL4 CRBN By Both Disrupting MEIS2-CRBN Association and Opposing Regulation of MEIS2 and CRBN Synthesis That Enhances IMiD Therapy in Multiple Myeloma

Harnessing Btki Therapy By CDK4/6i Control of T Effector Memory Cells and T Cell Surveillance in Mantle Cell Lymphoma

Combined Inhibition of CDK2 and BCL2 Overrides Resistance to Targeting BTK and CDK4/6 in Mantle Cell Lymphoma Therapy

Dynamic Immune Surveillance in Durable Clinical Response to Combined BTK and BCL2 Inhibition in MCL at Longitudinal Single-Cell Resolution

FOXO1 Dependent Transcription Network Is a Targetable Vulnerability of Mantle Cell Lymphoma

Disrupting GRINL1A Association with Cereblon Accelerates IKZF1/3 Degradation and IMiD Killing of Mantle Cell Lymphoma Cells By CDK4/6 Inhibition

T-Cell Clonal Expansion and Activation Associated with Durable Clinical Response to Dual BTK and CDK4/6 Inhibitor Therapy in Mantle Cell Lymphoma

Composite Copy Number Variation in CDK4 , CDKN2A and RB1 Predisposes Mantle Cell Lymphoma to Expansion of PD1+ Tumor Cells and Resistance to CDK4/6 Inhibitor Therapy as Revealed by Integrative Longitudinal scRNA-seq

A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma

Cooperative Repression of IRF4 and Induction of IRF7 By CDK4/6 Inhibition Sensitizes Mantle Cell Lymphoma Cells to IMiD-Mediated Apoptosis Independent of p16 Deletion or c-Myc Overexpression

A Phase I Trial of Ibrutinib Plus Palbociclib in Patients with Previously Treated Mantle Cell Lymphoma

PIK3IP1 Inhibition of PI3K in G1 Arrest Induced By CDK4 Inhibition Reprograms MCL for Ibrutinib Therapy

Cooperative Supression of MEIS2 Mediates Dexamethasone Enhancement of Lenalidomide Killing in Myeloma Cells

Inhibition of CDK4/CDK6 Sensitizes Myeloma to IMiD By Reducing the MEIS2 to Cereblon Ratio That Accelerates IKZF1 and IKZF3 Degradation

High-Dose Carfilzomib and Dexamethasone As First-Line Treatment in Symptomatic Multiple Myeloma

Clapd (Clarithromycin, Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma Overcomes Negative Prognostic Impact of Adverse Cytogenetics and Prior Resistance to Lenalidomide and Bortezomib

Sensitizing shRNA Screen for Molecular Targets in CDK4/CDK6-Based Combination Therapy in Multiple Myeloma

The Combination Of Palbociclib Plus Bortezomib Is Safe and Active In Patients With Previously Treated Mantle Cell Lymphoma: Final Results Of a Phase I Trial

Integrative Whole Transcriptome and Exome Sequencing Reveals Reprogramming Of Mantle Cell Lymphoma In Prolonged Early G1 Arrest For Clinical Response To Selective Inhibition Of CDK4 In Combination Therapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only